Home / Companies / Heaton K.S.
Company family
Heaton K.S.: medicine shortages
As of 2 Nov 2026, 4 Heaton K.S. products have a reported shortage across 1 countries, covering 3 medicines.
Products short4rank #367 of 464
Medicines3active ingredients
Countries1/16
New in 90 days1+1 vs market pace
Typical duration23 monthsmedian so far
Manufacturing50%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Solifenacin | 2 | 4 Nov 2024 | Manufacturing problem | 6/16 | |
| Buprenorphine, Combinations | 1 | 16 Dec 2024 | Commercial decision or withdrawal | 4/16 | |
| Metformin and Sitagliptin | 1 | 1 Oct 2026 | Commercial decision or withdrawal | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.